Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2023 Jun 28

PMID 37378711

Authors

Sudheer Kumar Vuyyuru

Virginia Solitano

Malcolm Hogan

John K MacDonald

Alexa Zayadi

Claire E Parker

Bruce E Sands

Remo Panaccione

Neeraj Narula

Brian G Feagan

Siddharth Singh

Vipul Jairath

Christopher Ma

Affiliations

Soon will be listed here.

Abstract

Background: Targeting interleukin-23 (IL-23) is an important therapeutic strategy for Crohn's disease (CD).

Aims: This systematic review and meta-analysis assessed the efficacy and safety of selective IL-23p19 and IL-12/23p40 inhibitors in patients with moderate-to-severe CD.

Methods: MEDLINE, Embase, and the Cochrane library (CENTRAL) were searched from inception to May 24, 2023, for randomized, placebo- or active comparator-controlled induction and/or maintenance trials of selective IL-23p19 and IL-12/23p40 inhibitors in pediatric and adult patients with CD. The primary outcome was the proportion of patients in clinical remission. Secondary outcomes were clinical response, endoscopic remission, endoscopic response, and safety. Data were pooled using a random-effects model. Risk of bias and certainty of evidence were assessed using the Cochrane risk of bias tool and the GRADE criteria, respectively.

Results: Eighteen trials (n = 5561) were included. Most studies were rated as low risk of bias. Targeting IL-23 was significantly superior to placebo for inducing clinical (risk ratio [RR] = 1.87, 95% confidence interval [CI] 1.58-2.21) and endoscopic (RR = 3.20, 95%CI 2.17-4.70) remission and maintaining clinical remission (RR = 1.39, 95%CI 1.10-1.77) (GRADE high certainty evidence for all outcomes). Subgroup analysis showed that targeting IL-23 was superior to placebo for inducing clinical remission in biologic-naïve (RR = 2.20, 95%CI 1.46-3.32, I = 0%, p = 0.39) and biologic-experienced patients (RR = 1.82, 95%CI 1.27-2.60, I = 56.5%, p = 0.01). Targeting IL-23 was associated with a decreased risk of serious adverse events in induction (RR = 0.55, 95%CI 0.44-0.73) and maintenance (RR = 0.72, 95%CI 0.53-0.98) trials compared to placebo (high certainty evidence).

Conclusion: Targeting IL-23 is effective and safe for inducing and maintaining clinical and endoscopic remission in patients with moderate-to-severe CD.

Citing Articles

Drug Development in Inflammatory Bowel Diseases: What Is Next?.

Petronio L, Dal Buono A, Gabbiadini R, Migliorisi G, Privitera G, Ferraris M Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006003 PMC: 11858795. DOI: 10.3390/ph18020190.

Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials.

Massironi S, Furfaro F, Bencardino S, Allocca M, Danese S J Gastroenterol. 2024; 59(9):761-787.

PMID: 38980426 PMC: 11339122. DOI: 10.1007/s00535-024-02130-x.

Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases.

Mignini I, Piccirilli G, Termite F, Paratore M, Esposto G, Laterza L Cells. 2024; 13(1).

PMID: 38201294 PMC: 10778449. DOI: 10.3390/cells13010090.

References

Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel J . Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018; 155(4):1045-1058. DOI: 10.1053/j.gastro.2018.06.035. View

Solitano V, Facciorusso A, Jess T, Ma C, Hassan C, Repici A . Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022; 21(4):907-921.e2. DOI: 10.1016/j.cgh.2022.07.032. View

Barberio B, Gracie D, Black C, Ford A . Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. Gut. 2022; 72(2):264-274. DOI: 10.1136/gutjnl-2022-328052. View

Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J, Danese S . Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022; 399(10340):2031-2046. DOI: 10.1016/S0140-6736(22)00466-4. View

Sandborn W, DHaens G, Reinisch W, Panes J, Chan D, Gonzalez S . Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022; 162(6):1650-1664.e8. DOI: 10.1053/j.gastro.2022.01.047. View

Lupardus P, Garcia K . The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol. 2008; 382(4):931-41. PMC: 2666310. DOI: 10.1016/j.jmb.2008.07.051. View

Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L . Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020; 34(12):2830-2838. PMC: 7818271. DOI: 10.1111/jdv.16521. View

Rahman P, Ritchlin C, Helliwell P, Boehncke W, Mease P, Gottlieb A . Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. J Rheumatol. 2021; 48(12):1815-1823. DOI: 10.3899/jrheum.201532. View

Singh S, Murad M, Fumery M, Sedano R, Jairath V, Panaccione R . Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021; 6(12):1002-1014. PMC: 8933137. DOI: 10.1016/S2468-1253(21)00312-5. View

10.

Gisbert J, Marin A, McNicholl A, Chaparro M . Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015; 41(7):613-23. DOI: 10.1111/apt.13083. View

11.

Sandborn W, Gasink C, Gao L, Blank M, Johanns J, Guzzo C . Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012; 367(16):1519-28. DOI: 10.1056/NEJMoa1203572. View

12.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

13.

Gordon K, Lebwohl M, Papp K, Bachelez H, Wu J, Langley R . Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2021; 186(3):466-475. PMC: 9298814. DOI: 10.1111/bjd.20818. View

14.

Sands B, Peyrin-Biroulet L, Kierkus J, Higgins P, Fischer M, Jairath V . Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology. 2021; 162(2):495-508. DOI: 10.1053/j.gastro.2021.10.050. View

15.

Feagan B, Sandborn W, DHaens G, Panes J, Kaser A, Ferrante M . Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017; 389(10080):1699-1709. DOI: 10.1016/S0140-6736(17)30570-6. View

16.

Moschen A, Tilg H, Raine T . IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2018; 16(3):185-196. DOI: 10.1038/s41575-018-0084-8. View

17.

Sands B, Jacobson E, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R . Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis. 2009; 16(7):1209-18. DOI: 10.1002/ibd.21159. View

18.

Zhu J, Paul W . Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev. 2010; 238(1):247-62. PMC: 2975272. DOI: 10.1111/j.1600-065X.2010.00951.x. View

19.

Sandborn W, Rebuck R, Wang Y, Zou B, Adedokun O, Gasink C . Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2021; 20(3):578-590.e4. PMC: 8374005. DOI: 10.1016/j.cgh.2021.02.025. View

20.

Feagan B, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman J . Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375(20):1946-1960. DOI: 10.1056/NEJMoa1602773. View